Lv2
190 积分 2022-02-18 加入
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
2天前
已完结
Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer
3个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
4个月前
已完结
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
4个月前
已完结
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
4个月前
已完结
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
4个月前
已关闭
Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management
5个月前
已完结
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials
5个月前
已完结
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
5个月前
已完结
Mobocertinib: First Approval
5个月前
已完结
皖公网安备34019202002308
